Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA) granted stock options to seven new employees to purchase an aggregate of 254,540 shares of common stock, effective August 3, 2026.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted stock options to seven new employees to purchase an aggregate of 254,540 shares of common stock, effective August 3, 2026. The awards were approved by the Compensation Committee under Olema’s 2022 Inducement Plan as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term and an exercise price of $11.28 per share, equal to the last reported sale price on August 3, 2026. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments, subject to continued employment.
Positive
- None.
Negative
- None.
Details
News Market Reaction – OLMA
In the Aug 5 session, OLMA declined 1.53%, reflecting a mild negative market reaction. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- New employees
- seven employees
- Inducement grants effective August 3, 2026
- Shares covered
- 254,540 shares
- Aggregate common-stock options granted
- Grant effective date
- August 3, 2026
- Date the options became effective
- Vesting period
- four years
- Option vesting schedule
- Initial vesting
- 25 percent
- Vests on the first anniversary
- Monthly installments
- 36 equal monthly installments
- Remaining vesting after the first anniversary
- Option term
- 10-year term
- Term of the stock options
- Exercise price
- $11.28 per share
- Equal to the August 3, 2026 Nasdaq last sale price
Historical Context
-
Options granted to eight employees under the inducement plan
-
Options granted to six employees under the inducement plan
-
Bayer collaboration evaluated OP-3136 with NUBEQA in prostate cancer
-
Initial OP-3136 data showed manageable effects and partial responses
-
Company announced participation in three healthcare investor conferences
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
inducement plan financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock, effective as of August 3, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.